{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3"}]}],"title":"CR"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"mCR"},{"categories":[{"measurements":[{"groupId":"OG000","value":"2"}]}],"title":"CRi"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}],"title":"No Response"}],"denoms":[{"counts":[{"groupId":"OG000","value":"6"}],"units":"Participants"}],"description":"Best Overall Response was determined for patients with HR-MDS. The number/percentage of patients with Complete Remission (CR), marrow Complete Remission (mCR), and No Response is summarized based on IWG criteria. The summary also includes the number/percentage of patients who demonstrated Complete Remission with incomplete hematologic recovery (CRi).","groups":[{"description":"Administration: Decitabine is reconstituted with 5 ml sterile water to facilitate subcutaneous administration. Decitabine is given by subcutaneous injection. Venetoclax is taken as a tablet prepared by patients pharmacy. Venetoclax is given at a dose of 400 mg po once per week concurrently with the Decitabine dose (+/- 1 day allowed ).\n\nVenetoclax: Venetoclax 400 mg po on days 1, 8, 15 and 22 of each cycle (28-day cycle)\n\nDecitabine: Decitabine 0.2 mg/kg SQ (subcutaneous) on days 2, 9, 16, 23 (for aggressive disease will add decitabine on days 3, 10, 17, 24)","id":"OG000","title":"Decitabine/Venetoclax (Single Arm)"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"6 patients who comprised the Primary Outcome analysis were part of the HR-MDS cohort.","reportingStatus":"POSTED","timeFrame":"At the time of censoring of data, up to ~21 months","title":"Best Overall Response in Patients With HR-MDS","type":"POST_HOC","unitOfMeasure":"Participants"}